Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 5 , Pages 511-518 , May 2009

Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study

,Accepted 8 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funding for this research was provided by Eli Lilly and Company.The authors thank Stephen W. Gutkin of Rete Biomedical Communications for assistance in manuscript preparation.Clinical trials registration information—Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00486122. Results of the other studies analyzed in the Integrated Data Exploratory Analysis study are posted at www.clinicalstudyresults.org, ID numbers 5670, 7972, 2746, 1585, 1586, and 3468, and www.lillytrials.com.

PII: S0890-8567(09)60068-X

doi: 10.1097/CHI.0b013e31819c55b2

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 5 , Pages 511-518 , May 2009

Article Tools

* Image Usage & Resolution